Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Furazolidone

FDA-approved product (tablet, oral), marketed as Furoxone.

Registered studies
49
Lab records
2
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Furazolidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Furazolidone. Its therapeutic class is shown instead.

WHO therapeutic group
Other antiinfectives and antiseptics
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC G01AX06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA23.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis91.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 2 of 2 lab records
Open Furazolidone in ChEMBL Registered studies below
Show the 2 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Furazolidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection

    NCT05126121 · start 2021-11-20

    Registered record
    Registry ID
    NCT05126121
    Conditions
    Helicobacter Pylori Infection
    Interventions
    three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-11-20
    Completion
    2022-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionthree kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection

    NCT05133193 · start 2021-11-20

    Registered record
    Registry ID
    NCT05133193
    Conditions
    Helicobacter Pylori Infection
    Interventions
    three kinds of antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-11-20
    Completion
    2022-06-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionthree kinds of antibiotics
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection

    NCT04991584 · start 2021-08-04

    Registered record
    Registry ID
    NCT04991584
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-04
    Completion
    2022-07-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
    PhaseNot applicable
    Registry statusUnknown

  • Differences in the Eradication of Helicobacter Pylori by Different Therapies

    NCT05097846 · start 2021-06-17

    Registered record
    Registry ID
    NCT05097846
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Group1 Vonoprazan Fumarate + amoxicillin + doxycycline; Group2 Vonoprazan Fumarate + furazolidone + doxycycline; Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline; Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-06-17
    Completion
    2022-10-17
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionGroup1 Vonoprazan Fumarate + amoxicillin + doxycycline; Group2 Vonoprazan Fumarate + furazolidone + doxycycline; Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline; Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

    NCT04907747 · start 2021-05-18

    Registered record
    Registry ID
    NCT04907747
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Vonoprazan; Esomeprazole; Colloidal bismuth pectin; Amoxicillin; Furazolidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-05-18
    Completion
    2022-04-13
    Enrolment
    234

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionVonoprazan; Esomeprazole; Colloidal bismuth pectin; Amoxicillin +1 more
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety Study of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection

    NCT05410223 · start 2021-04-06

    Registered record
    Registry ID
    NCT05410223
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth; IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth; Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline; IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-04-06
    Completion
    2022-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionYolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth; IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth; Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline; IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
    PhaseNot applicable
    Registry statusUnknown

  • Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection

    NCT05176821 · start 2021-01-01

    Registered record
    Registry ID
    NCT05176821
    Conditions
    H. Pylori Infection
    Interventions
    esomeprazole plus amoxicillin; amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-01-01
    Completion
    2022-12-31
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionH. Pylori Infection
    Interventionesomeprazole plus amoxicillin; amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole
    PhaseNot applicable
    Registry statusUnknown

  • A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication

    NCT04660123 · start 2020-12-20

    Registered record
    Registry ID
    NCT04660123
    Conditions
    Gastric Cancer; Helicobacter Pylori Infection; Bismuth
    Interventions
    Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-12-20
    Completion
    2021-12-30
    Enrolment
    959

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer; Helicobacter Pylori Infection; Bismuth
    InterventionBismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
    PhasePhase 4
    Registry statusCompleted

  • Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

    NCT04678492 · start 2020-12-20

    Registered record
    Registry ID
    NCT04678492
    Conditions
    Gastritis; Dyspepsia; Helicobacter Pylori Infection; Gastric Cancer; Peptic Ulcer
    Interventions
    Esomeprazole; Amoxicillin; Bismuth; Esomeprazole; Tetracycline; Furazolidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-12-20
    Completion
    2021-12-20
    Enrolment
    658

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastritis; Dyspepsia; Helicobacter Pylori Infection; Gastric Cancer +1 more
    InterventionEsomeprazole; Amoxicillin; Bismuth; Esomeprazole +2 more
    PhasePhase 4
    Registry statusCompleted

  • The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

    NCT04810793 · start 2020-07-01

    Registered record
    Registry ID
    NCT04810793
    Conditions
    Helicobacter Pylori
    Interventions
    Amoxicillin , Levofloxacin and Esomeprazole; Amoxicillin , Furazolidone and Esomeprazole; Tetracycline , Furazolidone and Esomeprazole; Amoxicillin,Levofloxacin and Vonoprazan fumarate; Amoxicillin,Furazolidone and Vonoprazan fumarate; Tetracycline,Furazolidone and Vonoprazan fumarate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2022-06-30
    Enrolment
    820

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori
    InterventionAmoxicillin , Levofloxacin and Esomeprazole; Amoxicillin , Furazolidone and Esomeprazole; Tetracycline , Furazolidone and Esomeprazole; Amoxicillin,Levofloxacin and Vonoprazan fumarate +2 more
    PhaseNot recorded
    Registry statusCompleted

  • Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin

    NCT04264663 · start 2019-11-01

    Registered record
    Registry ID
    NCT04264663
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Furazolidone; Tinidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-11-01
    Completion
    2022-12-30
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionFurazolidone; Tinidazole
    PhasePhase 4
    Registry statusUnknown

  • Effect of Probiotics on Helicobacter Pylori Eradication

    NCT04034641 · start 2019-06-17

    Registered record
    Registry ID
    NCT04034641
    Conditions
    Helicobacter Pylori Eradication
    Interventions
    Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy; Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-06-17
    Completion
    2021-12-31
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Eradication
    InterventionBifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy; Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
    PhasePhase 4
    Registry statusUnknown

  • Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection

    NCT03616405 · start 2019-04-01

    Registered record
    Registry ID
    NCT03616405
    Conditions
    Helicobacter Pylori Infection
    Interventions
    rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-04-01
    Completion
    2020-04-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionrabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
    PhasePhase 4
    Registry statusUnknown

  • The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection

    NCT03377933 · start 2019-03-15

    Registered record
    Registry ID
    NCT03377933
    Conditions
    Efficacy; Gastric Microbiota; Safety
    Interventions
    Compound Lactobacillus acidophilus
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-03-15
    Completion
    2020-03-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEfficacy; Gastric Microbiota; Safety
    InterventionCompound Lactobacillus acidophilus
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection

    NCT03726099 · start 2019-03-15

    Registered record
    Registry ID
    NCT03726099
    Conditions
    Helicobacter Pylori Infection
    Interventions
    esomeprazole, amoxicillin, furazolidone，tetracycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-03-15
    Completion
    2020-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionesomeprazole, amoxicillin, furazolidone，tetracycline
    PhasePhase 4
    Registry statusUnknown